Melatonin: Action as antioxidant and potential applications in human disease and aging

Toxicology

Volumn 278, Issue 1, 2010, Pages 55-67

  Bonnefont Rousselot, Dominique ^a,b   Collin, Fabrice ^c,d  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d LABORATOIRE HÉTÉROÉLÉMENTS ET COORDINATION   (France)

Author keywords

Aging; Free radicals; Gamma Radiolysis; Human disease; Mass spectrometry; Melatonin

Indexed keywords

1 (3 METHOXYPHENYL0 2 PROPYL 1,2,3,4 TETRAHYDROBETA CARBOLINE; 5 METHOXYTRYPTAMINE; FREE RADICAL; MELATONIN; MELATONIN DERIVATIVE; N ACETYL 6 METHOXYTRYPTAMINE; N ACETYLSEROTONIN; N NANOYL 5 METHOXYTRYPTAMINE; N [2 (5 METHOXY 1H INDOL 3 YL)ETHYL] 3,5 DI TERT BUTYL 4 HYDROXYBENZAMIDE; REACTIVE OXYGEN METABOLITE; SEROTONIN; UNCLASSIFIED DRUG;

AGING; ANTIOXIDANT ACTIVITY; ARTICLE; DIETARY INTAKE; HUMAN; INSOMNIA; JET LAG; MASS SPECTROMETRY; METABOLIC DISORDER; OXIDATIVE STRESS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 78149411295     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.04.008     Document Type: Article

References (175)

1. Abuja P.M., Liebmann P., Hayn M., Schauenstein K., Esterbauer H. Antioxidant role of melatonin in lipid peroxidation of human LDL. FEBS Lett. 1997, 413:289-293.
2. Allegra M., Reiter R.J., Tan D.X., Gentile C., Tesoriere L., Livrea M.A. The chemistry of melatonin's interaction with reactive species. J. Pineal Res. 2003, 34:1-10.
3. Anisimov V.N., Popovich I.G., Zabezhinski M.A., Anisimov S.V., Vesnushkin G.M., Vinogradova I.A. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim. Biophys. Acta 2006, 1757:573-589.
4. Arnao M.B., Hernández-Ruiz J. Assessment of different sample processing procedures applied to the determination of melatonin in plants. Phytochem. Anal. 2009, 20:14-18.
5. Ayano E., Suzuki Y., Kanezawa M., Sakamoto C., Morita-Murase Y., Nagata Y., Kanazawa H., Kikuchi A., Okano T. Analysis of melatonin using a pH- and temperature-responsive aqueous chromatography system. J. Chromatogr. A 2007, 1156:213-219.
6. Baydas G., Canatan H., Turkoglu A. Comparative analysis of the protective effects of melatonin and vitamin E on streptozocin-induced diabetes mellitus. J. Pineal Res. 2002, 32:225-230.
7. Betteridge D.J. What is oxidative stress?. Metabolism 2000, 49:3-8.
8. Beyer C.E., Steketee J.D., Saphier D. Antioxidant properties of melatonin-an emerging mystery. Biochem. Pharmacol. 1998, 56:1265-1272.
9. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007, 297:842-857.
10. Bolli R., Jeroudi M., Patel B., Aruoma O., Halliwell B., Lai E., McCay P. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ. Res. 1989, 65:607-622.
11. Bonnefont-Rousselot D., Chevé G., Gozzo A., Tailleux A., Guilloz V., Caisey S., Teissier E., Fruchart J.C., Delattre J., Jore D., Lesieur D., Duriez P., Gardès-Albert M. Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation. J. Pineal Res. 2002, 33:109-117.
12. Bonnefont-Rousselot D., Guilloz V., Lepage S., Bizard C., Duriez P., Lesieur D., Delattre J., Jore D., Gardès-Albert M. Protection of endogenous β-carotene in LDL oxidized by oxygen free radicals in the presence of supraphysiological concentrations of melatonin. Redox Report 2003, 8:95-104.
13. Bonnefont-Rousselot D. Gamma radiolysis as a tool to study lipoprotein oxidation mechanisms. Biochimie 2005, 86:903-911.
14. Brusco L.I., Marquez M., Cardinali D.P. Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J. Pineal Res. 1998, 25:260-263.
15. Brzezinski A. Mechanism of disease: melatonin in humans. N. Engl. J. Med. 1997, 336:186-195.
16. Bubenik G.A., Ayles H.L., Friedship M., Ball R.O., Brown G.M. Relationship between melatonin levels in plasma and gastrointestinal tissues and the incidence and severity of gastric ulcers in pigs. J. Pineal Res. 1998, 24:62-66.
17. Bubenik G.A. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig. Dis. Sci. 2002, 47:2336-2338.
18. Burkhardt S., Tan D.X., Manchester L.C., Hardeland R., Reiter R.J. Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (Prunus cerasus). J. Agric. Food Chem. 2001, 49:4898-4902.
19. Caballero B., Vega-Naredo I., Sierra V., Huidobro-Fernàndez C., Soria-Valles C., De Gonzalo-Calvo D., Tolivia D., Pallàs M., Camins A., Rodriguez-Colunga M.J., Coto-Montes A. Melatonin alters cell death processes in response to age-related oxidative stress in the brain of senescence-accelerated mice. J. Pineal Res. 2009, 46:106-114.
20. Calabrese V., Cornelius C., Mancuso C., Lentile R., Stella A.M., Butterfield D.A. Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol. Biol. 2010, 610:285-308.
21. Cao J., Murch S.J., O'Brien R., Saxena P.K. Rapid method for accurate analysis of melatonin, serotonin and auxin in plant samples using liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2006, 1134:333-337.
22. Cermakian N., Boivin D.B. The regulation of central and peripheral circadian clocks in humans. Obes. Rev. 2009, 2:25-36.
23. Charniot J.C., Bonnefont-Rousselot D., Marchand C., Zerhouni K., Vignat N., Peynet J., Plotkine M., Legrand A., Artigou J.Y. Oxidative stress implication in a new phenotype of amyotrophic quadricipital syndrome with cardiac involvement due to lamin A/C mutation. Free Radic. Res. 2007, 41:424-431.
24. Chen G., Huo Y., Tan D.-X., Liang Z., Zhang W., Zhang Y. Melatonin in Chinese medicinal herbs. Life Sci. 2003, 73:19-26.
25. Collin F., Bonnefont-Rousselot D., Yous S., Marchetti C., Jore D., Gardès-Albert M. Online H/D exchange liquid chromatography as a support for the mass spectrometric identification of the oxidation products of melatonin. J. Mass Spectrom. 2009, 44:318-329.
26. Curtin J.F., Donovan M., Cotter T.G. Regulation and measurement of oxidative stress in apoptosis. J. Immunol. Methods 2002, 265:49-72.
27. Dahlitz M., Alvarez B., Vignau J., English J., Arendt J., Parkes J.D. Delayed sleep phase syndrome response to melatonin. Lancet 1991, 337:1121-1124.
28. Dalle-Donne I., Rossi R., Colombo R., Giustarini D., Milzani A. Biomarkers of oxidative damage in human disease. Clin. Chem. 2006, 52:601-623.
29. De La Puerta C., Carrascosa-Salmoral M.P., Garcia-Luna P.P., Lardone P.J., Herrera J.L., Fernandez-Montesinos R., Guerrero J.M., Pozo D. Melatonin is a phytochemical in olive oil. Food Chem. 2007, 104:609-612.
30. Deng W.G., Tang S.T., Tseng H.P., Wu K.K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006, 108:518-524.
31. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid Y., Lees A.J., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1998, 52:381-389.
32. Dominguez-Rodriguez A., Abreu-Gonzalez P., Reiter R.J. Clinical aspects of melatonin in the acute coronary syndrome. Curr. Vasc. Pharmacol. 2009, 7:367-373.
33. Dollins A.B., Zhdanova I.V., Wurtman R.J., Lynch H.J., Deng M.H. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc. Natl. Acad. Sci. 1994, 91:1824-1828.
34. Draganic I.G., Draganic Z.D. The Radiation Chemistry of Water 1971, Academic Press, New York, p. 142.
35. Dubbels R., Reiter R.J., Klenke E., Goebel A., Schnakenberg E., Ehlers C., Schiwara H.W., Schloot W. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry. J. Pineal Res. 1995, 18:28-31.
36. Duell P.B., Wheaton D.L., Shultz A., Nguyen H. Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations. Clin. Chem. 1998, 44:1931-1936.
37. El-Missiry M.A., Fayed T.A., El-Sawy M.R., El-Sayed A.A. Ameliorative effect of melatonin against gamma-irradiation-induced oxidative stress and tissue injury. Ecotoxicol. Environ. Saf. 2007, 66:278-286.
38. Emerit J., Edeas M., Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 2004, 58:39-46.
39. Epsztejn S., Glickstein H., Picard V., Slotki I.N., Breuer W., Beaumont C., Cabantchik Z.I. H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties. Blood 1999, 94:3593-3603.
40. Faillace M.P., Cutrera R., Sarmiento M.I., Rosenstein R.E. Evidence for local synthesis of melatonin in golden hamster retina. Neurol. Rep. 1995, 6:2093-2095.
41. Favier A. Le stress oxydant. Intérêt conceptuel et expérimental dans la compréhension des mécanismes des maladies et potentiel thérapeutique. L'actualité chimique 2003, (November-December):108-115.
42. Feng Z., Zhang J.T. Protective effect of melatonin on β-amyloid induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic. Biol. Med. 2004, 37:1790-1801.
43. Fildes J.E., Yonan N., Keevil B.G. Melatonin-a pleiotropic molecule involved in pathophysiological processes following organ transplantation. Immunology 2009, 127:443-449.
44. Fisher-Wellman K., Bell H.K., Bloomer R.J. Oxidative stress and antioxidant defense mechanisms linked to exercise during cardiopulmonary and metabolic disorders. Oxid. Med. Cell Longev. 2009, 2:43-51.
45. Forrest C.M., Mackay G.M., Stoy N., Stone T.W., Darlington L.G. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br. J. Clin. Pharmacol. 2007, 64:517-526.
46. Fridovich I. Fundamental aspects of reactive oxygen species, or what's the matter with oxygen?. Ann. N. Y. Acad. Sci. 1999, 893:13-18.
47. Fulia F., Gitto E., Cuzzocrea S., Reiter R.J., Dugo L., Gitto P., Barberi S., Cordaro S., Barber I. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J. Pineal Res. 2001, 31:343-349.
48. García, J.J., Piñol-Ripoll, G., Martínez-Ballarín, E., Fuentes-Broto, L., Miana-Mena, F.J., Venegas, C., Caballero, B., Escames, G., Coto-Montes, A., Acuña-Castroviejo, D., 2010. Melatonin reduces membrane rigidity and oxidative damage in the brain of SAMP(8) mice. Neurobiol. Aging Jan 20 (Epub ahead of print).
49. Gardès-Albert M., Bonnefont-Rousselot D., Abedinzadeh Z., Jore D. Espèces réactives de l'oxygène. Comment l'oxygène peut-il devenir toxique?. L'actualité chimique 2003, November-December:91-96.
50. Gibbs F.P., Vriend J. The half-life of melatonin elimination from rat plasma. Endocrinology 1981, 109:1796-1798.
51. Gilad E., Cuzzocrea S., Zingarelli B., Salzman A.L., Szabo C. Melatonin is a scavenger of peroxynitrite. Life Sci. 1997, 60:PL169-PL174.
52. Gitto E., Tan D.X., Reiter R.J., Karbownik M., Manchester L.C., Cuzzocera S., Fula F., Barberi I. Individual and synergistic actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in liver homogenates. J. Pharm. Pharmacol. 2001, 53:1393-1401.
53. Gitto E., Karbownik M., Reiter R.J., Tan D.X., Cuzzocrea S., Chiurazzi P., Cordaro S., Corona G., Trimarchi G., Barberi I. Effects of melatonin treatment in septic newborns. Pediatr. Res. 2001, 50:756-760.
54. Gitto E., Reiter R.J., Cordaro S.P., La Rosa M., Chiurazzi P., Trimarchi G., Gitto P., Calabrò M.P., Barberi I. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am. J. Perinatol. 2004, 21:209-216.
55. Gozzo A., Lesieur D., Duriez P., Fruchart J.-C., Teissier E. Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model. Free Radic. Biol. Med. 1999, 26:1538-1543.
56. Gulcin I., Buyukokuroglu M.E., Oktay M., Kufrevioglu O.I. On the in vitro antioxidative properties of melatonin. J. Pineal Res. 2002, 33:167-171.
57. Gutierrez-Cuesta J., Tajes M., Jiménez A., Coto-Montes A., Camins A., Pallàs M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. J. Pineal Res. 2008, 45:497-505.
58. Haimov I., Lavie P. Melatonin-a chronobiotic and soporific hormone. Arch. Gerontol. Geriatr. 1997, 24:167-173.
59. Haimovich, B., Calvano, J., Haimovich, A.D., Calvano, S.E., Coyle, S.M., Lowry S.F., 2010. In vivo endotoxin synchronizes and suppresses clock gene expression in human peripheral blood leukocytes. Crit. Care Med. January 14 (Epub ahead of print).
60. Halliwell B., Gutteridge J.M.C. The antioxidants of the human extracellular fluids. Arch. Biochem. Biophys. 1990, 280:1-8.
61. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 1999, Oxford University Press. third ed.
62. Hardeland R. Antioxidative protection by melatonin. Endocrine 2005, 27:119-130.
63. Hardeland R., Pandi-Perumal S.R. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr. Metab. (Lond.) 2005, 2:22.
64. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11:298-300.
65. Harman D. The biologic clock: the mitochondria?. J. Am. Geriatr. Soc. 1972, 20:145-147.
66. Harthe C., Claudy D., Dechaud H., Vivien-Roels B., Pevet P., Claustrat B. Radioimmunoassay of N-acetyl-N-formyl-5-methoxykynuramine (AFMK): a melatonin oxidative metabolite. Life Sci. 2003, 73:1587-1597.
67. Hattori A., Migitaka H., Iigo M., Itoh M., Yamamoto K., Ohtani-Kaneko R., Hara M., Suzuki T., Reiter R.J. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem. Mol. Biol. Int. 1995, 35:627-634.
68. Hernandez-Ruiz J., Cano A., Arnao M.B. Melatonin acts as a growth-stimulating compound in some monocot species. J. Pineal Res. 2005, 39:137-142.
69. Holgrem A. Redox regulation of genes and cell function. Critical Review of Oxidative Stress and Aging 2003, vol. II:102-111. World Scientific.
70. Hsieh H.-M., Wu W.-M., Hu M.-L. Soy isoflavones attenuate oxidative stress and improve parameters related to aging and Alzheimer's disease in C57BL/6J mice treated with D-galactose. Food Chem. Toxicol. 2009, 47:625-632.
71. Huether G., Poeggeler B., Reimer A., George A. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci. 1992, 52:945-953.
72. Iriti M., Rossoni M., Faoro F. Melatonin content in grape: myth or panacea?. J. Sci. Food Agric. 2006, 86:1432-1438.
73. Jan J.E., Hamilton D., Seward N., Fast D.K., Freeman R.D., Landon M. Clinical trials of controlled-release melatonin in children with sleep-wake disorders. J. Pineal Res. 2000, 29:34-39.
74. Jung-Hynes B., Reiter R.J., Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J. Pineal Res. 2010, 48:9-19.
75. Karasek M. Melatonin, human aging, and age-related diseases. Exp. Gerontol. 2004, 89:1723-1729.
76. Kaya H., Oral B., Ozguner F., Tahan V., Babar Y., Delibas N. The effect of melatonin application on lipid peroxidation during cyclophosphamide therapy in female rats. Zentralbl. Gynakol. 1999, 12:499-502.
77. Kedziora-Kornatowska K., Szewczyk-Golec K., Czuczejko J., Pawluk H., van Marke de Lumen K., Kozakiewicz M., Bartosz G., Kedziora J. Antioxidative effects of melatonin administration in elderly primary essential hypertension patients. J. Pineal Res. 2008, 45:312-317.
78. Kedziora-Kornatowska K., Szewczyk-Golec K., Kozakiewicz M., Pawluk H., Czuczejko J., Kornatowski T., Bartosz G., Kedziora J. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J. Pineal Res. 2009, 46:333-337.
79. Kelly M.R., Loo G. Melatonin inhibits oxidative modification of human low-density lipoprotein. J. Pineal Res. 1997, 22:203-209.
80. Konturek S.J., Konturek P.C., Brzozowski T., Bubenik G.A. Role of melatonin in upper gastrointestinal tract. J. Physiol. Pharmacol. 2007, 58(Suppl. 6):23-52.
81. Kontush A. Amyloid-β: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic. Biol. Med. 2001, 31:1120-1131.
82. Koppisetti S., Jenigiri B., Terron M.P., Tengattini S., Tamura H., Flores L.J., Tan D.X., Reiter R.J. Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review. Dig. Dis. Sci. 2008, 53:2592-2603.
83. Korkmaz A., Reiter R.J. Epigenetic regulation: a new research area for melatonin?. J. Pineal Res. 2008, 44:41-44.
84. Korkmaz A., Topal T., Tan D.X., Reiter R.J. Role of melatonin in metabolic regulation. Rev. Endocr. Metab. Disord. 2009, 10:261-270.
85. Korkmaz A., Reiter R.J., Topal T., Manchester L.C., Oter S., Tan D.X. Melatonin: an established antioxidant worthy of use in clinical trials. Mol. Med. 2009, 15:43-50.
86. Kücükakin B., Gögenur I., Reiter R.J., Rosenberg J. Oxidative stress in relation to surgery: is there a role for the antioxidant melatonin?. J. Surg. Res. 2009, 152:338-347.
87. Kuller L.H. A time to stop prescribing antioxidant vitamins to prevent and treat heart diseases?. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1253.
88. Lee P.P.N., Shin S.Y.W., Chow P.H., Pang S.F. Regional and diurnal studies of melatonin binding sites in the duck gastrointestinal tract. Biol. Signals 1995, 4:212-224.
89. Leone A.M., Francis P.L., Silman R.E. The isolation, purification, and characterisation of the principal urinary metabolites of melatonin. J. Pineal Res. 1987, 4:253-266.
90. Leston J., Harthé C., Brun J., Mottolese C., Mertens P., Sindou M., Claustrat B. Melatonin is released in the third ventricle in humans. A study in movement disorders. Neurosci. Lett. 2010, 469:294-297.
91. Li J.H., Yu J.P., Yu H.G., Xu X.M., Yu L.L., Liu J., Luo H.S. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005, 2005:185-193.
92. Lioe H., O'Hair R.A.J., Reid G.E. Gas-phase reactions of tryptophan. J. Am. Soc. Mass. Spectrom. 2004, 15:65-76.
93. Lissoni P., Barni S., Meregalli S., Fossati V., Cazzaniga M., Esposti D., Tancini G. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br. J. Cancer 1995, 71:854-856.
94. Livrea M.A., Tesoriere L., D'Arpa D., Morreale M. Reaction of melatonin with lipoperoxyl radicals in phospholipid bilayers. Free Radic. Biol. Med. 1997, 23:706-711.
95. Longatti P., Perin A., Rizzo V., Comai S., Giusti P., Costa C.V. Ventricular cerebrospinal fluid melatonin concentrations investigated with an endoscopic technique. J. Pineal Res. 2007, 42:113-118.
96. Luza S., Speisky H. Liver copper storage and transport during development: implications for cytotoxicity. Am. J. Clin. Nutr. 1996, 63:812S-820S.
97. Manchester L.C., Tan D.X., Reiter R.J., Park W., Monis K., Qi W. High levels of melatonin in the seeds of edible plants: possible function in germ tissue protection. Life Sci. 2000, 67:3023-3029.
98. Martinez-Cruz F., Pozo D., Osuna C., Espinar A., Marchante C., Guerrero J.M. Oxidative stress induced by phenylketonuria in the rat: Prevention by melatonin, vitamin E, and vitamin C. J. Neurosci. Res. 2002, 69:550-558.
99. Matuszak Z., Reszka K.J., Chignell C.F. Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations. Free Radic. Biol. Med. 1997, 23:367-372.
100. Mekhloufi J., Bonnefont-Rousselot D., Yous S., Lesieur D., Couturier M., Thérond P., Legrand A., Jore D., Gardès-Albert M. Antioxidant activity of melatonin and a pinoline derivative on linoleate model system. J. Pineal Res. 2005, 39:27-33.
101. Mekhloufi J., Vitrac H., Yous S., Duriez P., Jore D., Gardès-Albert M., Bonnefont-Rousselot D. Quantification of the water/lipid affinity of melatonin and a pinoline derivative in lipid models. J. Pineal Res. 2007, 42:330-337.
102. Melchiorri D., Sewerynek E., Reiter R.J., Ortiz G.G., Poeggeler B., Nistico G. Suppressive effect of melatonin administration on ethanol-induced gastrointestinal injury in rats in vivo. Br. J. Pharmacol. 1997, 121:264-270.
103. Messner M., Hardeland R., Rodenbeck A., Huether G. Tissue retention and subcellular distribution of continuously infused melatonin in rats under near physiological conditions. J. Pineal Res. 1998, 25:251-259.
104. Millán-Plano S., Piedrafita E., Miana-Mena F.J., Fuentes-Broto L., Martínez-Ballarín E., López-Pingarrón L., Sáenz M.A., García J.J. Melatonin and structurally-related compounds protect synaptosomal membranes from free radical damage. Int. J. Mol. Sci. 2010, 11:312-328.
105. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142:37-46.
106. Mills E., Wu P., Seely D., Guyatt G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J. Pineal Res. 2005, 39:360-366.
107. Mistraletti, G., Sabbatini, G., Taverna, M., Figini, M.A., Magni, P., Ruscica, M., Dozio, E., Esposti, R., Demartini, G., Fraschini, F., Rezzani, R., Reiter, R.J., Iapichino, G., 2010. Pharmackinetics of orally administered melatonin in critically ill patients. J. Pineal Res. January 8 (Epub ahead of print).
108. Motoyama A., Taketoshi K., Namba R. Direct determination of endogenous melatonin in human saliva by column-switching semi-microcolumn liquid chromatography/mass spectrometry with on-line analyte enrichment. Rapid Commun. Mass Spectrom. 2004, 18:1250-1258.
109. Nordlund J.J., Lerner A.B. The effects of oral melatonin on skin color and on the release of pituitary hormones. J. Clin. Endocrinol. Metab. 1977, 45:768-774.
110. Ochoa J.J., Vilchez M.J., Palacios M.A., Garcia J.J., Reiter R.J., Munoz-Hoyos A. Melatonin protects against lipid peroxidation and membrane rigidity in erythrocytes from patients undergoing cardiopulmonary bypass surgery. J. Pineal Res. 2003, 35:104-108.
111. Okado-Matsumoto A., Fridovich I. Subcelllar distribution of superoxide dismutases (SOD) in rat liver. Cu,Zn-SOD in mitochondria. J. Biol. Chem. 2001, 296:38388-38393.
112. Owuor E.D., Kong A.N. Antioxidants and oxidants regulated signal transduction pathways. Biochem. Pharmacol. 2002, 64:765-770.
113. Pape C., Lüning K. Quantification of melatonin in phototrophic organisms. J. Pineal Res. 2006, 41:157-165.
114. Pappolla M.A., Chyan Y.J., Poeggler B., Frangione B., Wilson G., Chiso J., Reiter R.J. An assessment of the antioxidant and antimyloidogenic properties of melatonin: implications for Alzheimer's disease. J. Neural Transm. 2000, 107:203-231.
115. Pappolla M.A., Reiter R.J., Bryant-Thomas T.K., Poeggeler B. Oxidative mediated neurodegeneration in Alzheimer's disease: Melatonin and related antioxidants as neuroprotective agents. Curr. Med. Chem. 2003, 3:233-243.
116. Paredes S.D., Korkmaz A., Manchester L.C., Tan D.-X., Reiter R.J. Phytomelatonin: a review. J. Exp. Bot. 2009, 60:57-69.
117. Petrie K., Dawson A.G., Thompson L., Brook R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol. Psychiatry 1993, 33:526-530.
118. Pieri C., Marra M., Moroni F., Recchioni R., Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci. 1994, 55:PL271-PL276.
119. Pieri C., Marra M., Gaspar R., Damjanovich S. Melatonin protects LDL from oxidation but does not prevent the apolipoprotein derivatization. Biochem. Biophys. Res. Commun. 1996, 222:256-260.
120. Poeggeler B., Thuermann S., Dose A., Schoenke M., Burkhardt S., Haderland R. Melatonin's unique radical scavenging properties-roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res. 2002, 33:20-30.
121. Reiter R.J. The pineal and its hormones in the control of reproduction in mammals. Endocr. Rev. 1980, 1:109-131.
122. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 1991, 12:151-180.
123. Reiter R.J., Tan D.X., Osuna C., Gitto E. Actions of melatonin in the reduction of oxidative stress: a review. J. Biomed. Sci. 2000, 7:444-458.
124. Reiter R.J., Tan D.X., Sainz R.M., Mayo J.C., Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 2002, 54:1299-1321.
125. Reiter J.R., Tan D.X. What constitutes a physiological concentration of melatonin? J. Pineal Res. 2003, 34:79-80.
126. Reiter R.J., Tan D.X., Gitto E., Sainz R.M., Mayo J.C., Leon J., Manchester L.C., Vijayalaxmi, Kilic E., Kilic U. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol. J. Pharmacol. 2004, 56:159-170.
127. Reiter R.J., Manchester L.C., Tan D.-X. Melatonin in walnuts: Influence on levels of melatonin and total antioxidant capacity of blood. Nutrition 2005, 21:920-924.
128. Reiter R.J., Tan D.X., Maldonado M.D. Melatonin as an antioxidant: physiology versus pharmacology. J. Pineal Res. 2005, 39:215-216.
129. Reiter R., Gultekin F., Flores L.J., Terron M.P., Tan D.X. Melatonin: potential utility for improving public health. TAF Prev. Med. Bull. 2006, 5:131-158.
130. Rizzi A., Comai S., Bertazzo A., Costa C.V.L., Allegri G., Traldi P. An investigation on the possible role of melatonin in melanogenesis. J. Mass Spectrom. 2006, 41:517-526.
131. Rizzo M., Kotur-Stevuljevic J., Berneis K., Spinas G., Rini G.B., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V., Vekic J. Atherogenic dyslipidemia and oxidative stress: a new look. Transl. Res. 2009, 153:217-223.
132. Roberts J.E., Hu D.H., Wishart J.F. Pulse radiolysis studies of melatonin and chloromelatonin. J. Photochem. Photobiol. B 1998, 42:125-132.
133. Rodriguez C., Mayo J.C., Sainz R.M., Antolín I., Herrera F., Martín V., Reiter R.J. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 2004, 36:1-9.
134. Rolcik J., Lenobel R., Siglerova V., Strnad M. Isolation of melatonin by immunoaffinity chromatography. J. Chromatogr. B 2002, 775:9-15.
135. Rubio V.C., Sanchez-Vazquez F.J., Madrid J.A. Oral administration of melatonin reduces food intake and modifies macronutrient in European see bass (Dicentrarchus labrax, L.). J. Pineal Res. 2004, 37:42-47.
136. Salmon A.B., Richardson A., Pérez V.L. Update on the oxidative stress theory of aging: does oxidative stress play a role in aging or healthy aging?. Free Radical Biol. Med. 2010, 48:642-655.
137. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J. Mol. Cell. Cardiol. 2002, 34:379-388.
138. Schaffazick S.R., Pohlmann A.R., de Cordora C.A.S., Creczynski-Pasa T.B., Guterres S.S. Protective properties of melatonin-leaded nanoparticles against lipid peroxidation. Int. J. Pharm. 2005, 289:209-213.
139. Seabra M.L., Bignotto M., Pinto L.R., Tufik S. Randomized double blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J. Pineal Res. 2000, 29:193-200.
140. Shida C.S., Castrucci A.M.L., Lamy-Freund M.T. High melatonin solubility in aqueous medium. J. Pineal Res. 1994, 16:198-201.
141. 1-acetyl-5-methoxykynuramine, by activated leukocytes. J. Pineal Res. 2004, 37:171.
142. Skinner D.C., Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen Vein blood recirculating through the choroids plexus. Endocrinology 1999, 140:4399-4405.
143. Slominski A., Pisarchik A., Semak I., Sweatman T., Wortsman J., Szczesniewski A., Slugocki G., McNulty J., Kauser S., Tobin D.J., Jing C., Johansson O. Serotonergic and melatoninergic systems are fully expressed in human skin. FASEB J. 2002, 30:243-247.
144. Spinks, J.W.T., Woods, R.J., 1990. Water and inorganic aqueous systems, in: Introduction to Radiation Chemistry, John Wiley & Sons, Inc. (Eds.), third ed., pp. 243-313 (Chapter 7).
145. Srinivasan V., Spence D.W., Moscovitch A., Pandi-Perumal S.R., Trakht I., Brown G.M., Cardinali D.P. Malaria: therapeutic implications of melatonin. J. Pineal Res. 2010, 48:1-8.
146. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modification of low-density lipoprotein that increases its atherogenicity. N. Engl. J. Med. 1989, 320:915-924.
147. Steinberg D., Lewis A. Conner memorial lecture. Oxidative modification of LDL and atherogenesis. Circulation and atherogenesis. Circulation 1997, 95:1062-1071.
148. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84:1381-1478.
149. Sun F.Y., Lin X., Mao L.Z., Ge W.H., Zhang L.M., Huang Y.L., Gu J. Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J. Pineal Res. 2002, 33:48-56.
150. Tailleux A., Gozzo A., Torpier G., Martin-Nizard F., Bonnefont-Rousselot D., Lemdani M., Furman C., Foricher R., Chevé G., Yous S., Micard F., Bordet R., Gardès-Albert M., Lesieur D., Teissier E., Fruchart J.C., Fiévet C., Duriez P. Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression. J. Cardiovasc. Pharmacol. 2005, 46:241-249.
151. Tamura H., Takasaki A., Miwa I., Taniguchi K., Maekawa R., Asada H., Taketani T., Matsuoka A., Yamagata Y., Shimamura K., Morioka H., Ishikawa H., Reiter R.J., Sugino N. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J. Pineal Res. 2008, 44:280-287.
152. Tan D.X., Chen L.D., Poeggeler B., Manchester L.D., Reiter R.J. Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocr. J. 1993, 1:57-60.
153. Tan D., Reiter R.J., Chen L.D., Poeggeler B., Manchester L.C., Barlow-Walden L.R. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis 1994, 15:215-218.
154. Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintraub S.T., Vijayalaxmi, Shepard A.M.M. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 1998, 253:614-620.
155. Tan D.X., Manchester L.C., Reiter R.J., Qi W., Hanes M.A., Farley N.J. High physiological levels of melatonin in bile of mammals. Life Sci. 1999, 65:2523-2529.
156. Tan D.X., Manchester L.C., Reiter R.J., Qi W.B., Zhang M., Weintraub S.T., Cabrera J., Sainz R.M., Mayo J.C. Identification of high elevated levels of melatonin in bone marrow: its origin and significance. Biochim. Biophys. Acta 1999, 1472:206-214.
157. Tan D.X., Reiter R.J., Manchester L.C., Yan M.T., El Sawi M., Sainz R.M., Mayo J.C., Kohen R., Allegra M., Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2002, 2:181-197.
158. Terry P.D., Villinger F., Bubenik G.A., Sitaraman S.V. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm. Bowel Dis. 2009, 15:134-140.
159. Topal T., Oztas Y., Korkmaz A., Sadir S., Oter S., Coskun O., Bilgic H. Melatonin ameliorates bladder damage induced by cyclophosphamide in rats. J. Pineal Res. 2005, 38(4):272-277.
160. Tricoire H., Loatelli A., Chemineau P., Malpaux B. Melatonin enters cerebrospinal fluid through the pineal recess. Endocrinology 2002, 143:184-190.
161. Ucar M., Korkmaz A., Reiter R.J., Yaren H., Oter S., Kurt B., Topal T. Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard. Toxicol. Lett. 2007, 173:124-131.
162. Van Tassel D.L., Roberts N., Lewy A., O'Neill S.D. Melatonin in plant organs. J. Pineal Res. 2001, 31:8-15.
163. Vijayalaxmi, Reiter R.J., Meltz M.L. Melatonin protects human blood lymphocytes from radiation induced chromosome damage. Mutat. Res. 1995, 34:623-631.
164. Vijayalaxmi, Reiter R.J., Herman T.S., Meltz M.L. Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers. Mutat. Res. 1996, 37:221-228.
165. Vijayalaxmi, Reiter R.J., Meltz M.L. Melatonin: possible mechanisms involved in its "radioprotective" effect. Mutat. Res. 1998, 404:187-189.
166. Vijayalaxmi, Reiter R.J., Tan D.X., Herman T.S., Thomas C.R. Melatonin as a radioprotective agent: a review. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:639-653.
167. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A., Topol E.J. Use of antioxidant vitamins fort he prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet 2003, 361:2017-2023.
168. Walters-Laporte E., Furman C., Fouquet S., Martin-Nizard F., Lestavel S., Gozzo A., Lesieur D., Fruchart J.C., Duriez P., Teissier E. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells. J. Cardiovasc. Pharm. 1998, 32:582-592.
169. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther. 2009, 15:345-357.
170. Winiarska K., Fraczyk T., Malinska D., Drosaz J., Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J. Pineal Res. 2006, 40:168-176.
171. Wirz-Justice A., Werth E., Renz C., Müller S., Kräuchi K. No evidence for a phase delay in human circadian rhythms after a single morning melatonin administration. J. Pineal Res. 2002, 32:1-5.
172. Yang S., Zheng X., Xu Y., Zhou X. Rapid determination of serum melatonin by ESI-MS-MS with direct sample injection. J. Pharm. Biomed. Anal. 2002, 30:781-790.
173. Yun H.Y., Dawson V.L., Dawson T.M. Neurobiology of nitric oxide. Crit. Rev. Neurobiol. 1996, 10:291-316.
174. Zang L.Y., Cosma G., Gardner H., Vallyathan V. Scavenging of reactive oxygen species by melatonin. Biochim. Biophys. Acta 1998, 1425:469-477.
175. Zureik M., Galan P., Bertrais S., Mennen L., Czernichow S., Blacher J., Ducimetiere P., Hercberg S. Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. Arterioscler. Thromb. Vasc. Biol. 2004, 1485-1491.